Heart Failure Treatment Options and Clinical Trials | Ancora Heart
WEBAncora Heart, a medical device company, has developed AccuCinch®, the first percutaneous ventricular restoration system designed to treat heart failure.
ANCORA HEART’S ACCUCINCH SYSTEM DEMONSTRATES …
WEBFor patients in whom HF has progressed beyond the ability of medications and pacemakers to manage symptoms, the AccuCinch System may provide a new treatment option to fill the gap between medication or pacemaker therapy and left ventricular assist devices (LVADs) or a heart transplant.
Transcatheter Left Ventricular Restoration in Patients With Heart ...
WEBFeb 28, 2023 · In patients with heart failure with reduced ejection fraction without significant mitral regurgitation receiving optimal medical therapy, the AccuCinch System resulted in decreases of LV volume, as well as improved quality of life and exercise endurance. A randomized trial is ongoing (NCT04331769).
Ancora Heart Receives Breakthrough Device Designation from …
WEBCurrently being evaluated in the CORCINCH-HF pivotal clinical trial, the AccuCinch System is designed to provide a minimally invasive treatment option for patients who have symptomatic heart failure (HF) with reduced ejection fraction (HFrEF).
Randomized Clinical Evaluation of the AccuCinch® Ventricular ...
WEBJun 9, 2024 · The CORCINCH-HF Study is evaluating the safety and efficacy of the AccuCinch® Ventricular Restoration System, a new and innovative device-based approach to treating heart failure that is designed to improve the structure and function of the heart and may help reduce symptoms, improve quality of life and potentially increase life expectancy.
Device Therapy in Chronic Heart Failure: - Journal of the …
WEBThe AccuCinch Guided Delivery system (Ancora Heart, Inc) is a direct device-based, catheter-delivered basilar ventriculoplasty system that involves implantation of anchors under the posterior mitral annulus, thus resulting in reduction of the septal-free wall dimension, approximation of the papillary muscles and the mitral leaflets, and ...
Ancora Heart AccuCinch - Business Wire
WEBNov 8, 2021 · Ancora Heart's proprietary AccuCinch® Ventricular Restoration System is the only completely transcatheter device designed to restore the structure and function of the enlarged left ventricle...
CORCINCH-HF Pivotal Trial Begins for Ancora Heart’s AccuCinch …
WEBJan 28, 2021 · The transcatheter AccuCinch system is designed to treat the enlarged left ventricle by improving the structure and function of the heart and help bring relief to HF patients who remain symptomatic despite current guideline-directed medical care.
FDA Gives Breakthrough Device Designation to Ancora Heart’s AccuCinch …
WEBJul 18, 2022 · The FDA granted Santa Clara, Calif.-based Ancora Heart a Breakthrough Device designation for its AccuCinch ventricular restoration system. The device is intended to provide a minimally invasive treatment option for patients who have symptomatic heart failure with reduced ejection fraction.
Promising Preliminary Results for AccuCinch LV Restoration …
WEBMar 21, 2023 · BOSTON, MA—The investigational AccuCinch system (Ancora Heart) for transcatheter left ventricular restoration (TLVR) has a favorable safety profile and appears to improve echocardiographic endpoints and patient-centered outcomes in patients with heart failure with reduced ejection fraction (HFrEF) who …
Skip to content